| Trial ID: | L1257 |
| Source ID: | NCT01549769
|
| Associated Drug: |
Bardoxolone Methyl
|
| Title: |
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Renal Insufficiency, Chronic|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Bardoxolone Methyl
|
| Outcome Measures: |
Primary: Area under the curve, 24 hours | Secondary: Time to maximum observed concentration, 56 days|Area under the plasma concentration-time curve, 0 to last observed concentration|Maximum observed concentration, 56 days
|
| Sponsor/Collaborators: |
Sponsor: Reata, a wholly owned subsidiary of Biogen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-04-30
|
| Completion Date: |
2013-10-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-02-02
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01549769
|
